盐酸多佐胺

Pharm. Dev. Technol. 19(6) , 748-54, (2014)

The objective of this work was to formulate and characterize non-ionic surfactant vesicles (niosomes) as an ocular carrier of dorzolamide hydrochloride (Dorzo); one of the antiglaucoma drugs. Niosomes were prepared of Cholesterol (Chol) with sorbitan monoeste...

PLoS ONE 7 , e33593, (2012)

Examination of the response of the retinal proteome to elevated intraocular pressure (IOP) and to the pharmacological normalization of IOP is crucial, in order to develop drugs with neuroptorective potential. We used a hereditary rat model of ocular hypertens...

Curr. Med. Res. Opin. 28(4) , 543-50, (2012)

To evaluate the efficacy of α2-adrenergic agonist (AA) brimonidine and topical carbonic anhydrase inhibitors (CAIs) dorzolamide and brinzolamide in reducing intraocular pressure (IOP) when used as adjunctive therapy to β-blockers (BBs) or prostaglandin analog...

Semin. Ophthalmol. 28(2) , 61-7, (2013)

To evaluate prospectively whether anti-glaucomatic drugs administered prior to intravitreal anti-vascular endothelial growth factor (VEGF) injection bevacizumab (Avastin,® Roche) or ranibizumab (Lucentis,® Novartis) prevents intraocular hypertension after the...

Klin. Monbl. Augenheilkd. 230(2) , 146-9, (2013)

Since their introduction the local carbonic anhydrase inhibitors (CAH) dorzolamide and brinzolamide have become well established in the drug therapy of glaucoma. They lower intraocular pressure (IOP) by blocking specifically carbonic anhydrase in the ciliary ...

Curr. Eye Res. 37 , 1107-1113, (2012)

Carbonic anhydrase inhibitors (CAIs) are used to reduce aqueous production in glaucoma, which includes a direct effect on the ciliary body. However, CAIs also affect ciliary blood flow, but the mechanisms of action of CAIs on the tone of intraocular ciliary a...

Expert Opin. Pharmacother. 13(13) , 1829-35, (2012)

The purpose of this study was to verify the ocular comfort of a fixed topical combination of brinzolamide 1% plus timolol 0.5% suspension vs. dorzolamide 2% plus timolol 0.5% solution, both preserved with benzalkonium chloride (BAK), in patients with primary ...

J. AAPOS 17(1) , 105-7, (2013)

Iris anomalies associated with congenital or early-childhood glaucoma include stable primary developmental abnormalities such as those associated with the Axenfeld-Rieger spectrum and aniridia. Secondary generalized iris atrophy from uncontrolled intraocular ...

Jpn. J. Ophthalmol. 56(6) , 559-63, (2012)

To investigate the ocular hypotensive effect and safety of dorzolamide hydrochloride 1 %/timolol maleate 0.5 % fixed-combination eye drops.The study cohort comprised 34 patients with either primary open-angle glaucoma or ocular hypertension who were being con...

J. Ocul. Pharmacol. Ther. 31(1) , 57-60, (2015)

We investigated the transcorneal penetration of commercial ophthalmic formulations containing timolol maleate in rabbit eyes.One drop (30 μL) of each ophthalmic solution (Xalacom(®), DuoTrav(®), Cosopt(®), and Timoptol(®)) was administered to the conjunctival...